Noreen Roth Henig's most recent trade in Avidity Biosciences Inc was a trade of 22,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 22,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 22,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 13,489 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 11,323 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 10,034 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 9,534 | 0 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2026 | 6,692 | 0 | - | - | Common Stock | |
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 10,034 | 10,034 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 6,692 | 6,692 | - | 0 | Common Stock | |
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 13,489 | 13,489 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 300,000 | 300,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 300,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 280,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 280,000 | 280,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 220,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 220,000 | 220,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 180,000 | 180,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 180,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Avidity Biosciences Inc | Noreen Roth Henig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Noreen Roth Henig | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2023 | 220,000 | 220,000 | - | - | Employee Stock Option (right to buy) |